Product InformationRegistration Status: Inactive
THIS PRODUCT HAS BEEN DEREGISTERED!
BETAFERON FOR INJECTION 0.25mg/ML is approved to be sold in Singapore with effective from 1999-11-19. It is marketed by BAYER (SOUTH EAST ASIA) PTE LTD, with the registration number of SIN11228P.
This product contains Interferon Beta-1B 0.25mg/ml in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by Boehringer Ingelheim Pharma GmbH & CoKG in GERMANY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
Mechanism of Action
Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.
* 9.4 – 28.9 mL/min•kg-1 [patients with diseases other than MS receiving single intravenous doses up to 2.0 mg]
Interferon beta 1b (recombinant) | Interferon beta-1b,recombinant | Interferon-beta-1b | Recombinant interferon beta-1b | Interferon beta-1b |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.